Form 4: Teva Pharmaceutical Executive VP Richard Daniell Reports Share Sale

Executive VP of European Commercial at Teva Pharmaceutical Industries, Richard Daniell, reports the sale of 20,599 ordinary shares on February 28, 2024, along with the vesting of restricted share units.

Summary

• Richard Daniell, Executive VP of European Commercial at Teva Pharmaceutical Industries, reported a transaction involving the company's ordinary shares on February 28, 2024.
• Daniell sold 20,599 ordinary shares at a weighted average price of $13.116 per share, with prices ranging from $13.01 to $13.19.
• The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 13, 2023.
• Additionally, 20,599 restricted share units vested on February 28, 2024.
• Following the reported transactions, Daniell beneficially owns 69,770 ordinary shares.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing an executive's share sale under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment, but rather a standard corporate practice.

Industry Context

Executive share sales are a common occurrence in publicly traded companies and are often related to compensation and diversification strategies. The use of a 10b5-1 trading plan suggests the executive planned these sales in advance to avoid accusations of insider trading.

Comparison to Industry Standards

• Executive compensation packages often include restricted share units that vest over time, aligning executive interests with long-term shareholder value.
• Rule 10b5-1 trading plans are a standard practice among corporate executives to manage the sale of company stock while mitigating insider trading concerns.
• Comparing Daniell's transactions to those of executives at similar pharmaceutical companies (e.g., Pfizer, Novartis) would provide a benchmark for assessing the scale and frequency of such activities.

Stakeholder Impact

• The share sale could have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.
• The vesting of restricted share units is part of the executive's compensation package, aligning their interests with the company's performance.

Key Dates